Belgin ALTUN, Ufuk ÖNDE, Zeliha KOÇAK TUFAN, Sami KINIKLI, Ali Pekcan DEMİRÖZ, Şerife ALTUN

Growing OXA-23 type strains among carbapenem-resistant Acinetobacter baumannii and tigecycline as an alternate combination therapy

Background/aim: The increasing prevalence and global spread of difficult-to-treat carbapenem-resistant Acinetobacter baumannii has become a serious problem. The aim of this study is to investigate the resistance patterns and tigecycline sensitivity of carbapenemresistant A. baumannii strains. Materials and methods: Acinetobacter strains that were carbapenem-resistant and collected mainly from intensive care units were included into this study. The antibiotic sensitivity/resistance of the strains to other antibiotics and tigecycline were noted. Presence of blaOXA-23, blaOXA-48, blaOXA-58, and NDM-1 was investigated by PCR. Results: In total, 44 carbapenem-resistant A. baumannii strains were detected. In addition, 57% (25/44) showed resistance to netilmicin and 2% (1/43) to tigecycline. All of the strains were susceptible to colistin. blaOXA-58 was found only in one (2%) strain while blaOXA-23 was found in 14 (32%) strains. All strains were negative for blaOXA-48 and NDM-1. Conclusion: blaOXA-23 was the main resistance pattern in carbapenem-resistant A. baumannii strains. blaOXA-58 was present only in one strain and no blaOXA-48 was found. Tigecycline susceptibility is high and it can be a treatment option for a possible combination therapy of carbapenem-resistant A. baumannii, especially for those for whom colistin is contraindicated because of its toxicity.

PDF

___

1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471 3484.
2. Poirel L, Lebessi E, Héritier C, Patsoura A, Foustoukou M, Nordmann P. Nosocomial spread of OXA-58-positive carbapenem-resistant Acinetobacter baumannii isolates in a paediatric hospital in Greece. Clin Microbiol Infect 2006; 12: 1138-1141.
3. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010; 23: 332-339.
4. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect Dis 2006; 12: 826-836.
5. Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol 2007; 2: 501-512.
6. Brown S, Amyes S. OXA (beta)-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 2006; 57: 1-3.
7. Gur D, Korten V, Unal S, Despande LM, Castanheria M. Increasing carbapenem resistance due to the clonal dissemination of oxallinase (OXA-23 and OXA-58) producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol 2008; 57: 1529-1532.
8. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CE, Harbarth S, Hindler JF, Kahlmeter G, OlssonLiljequist B et al. Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-281.
9. Olsvik Q, Strockbine NA. PCR detection of heat-stable, heatlabile, and Shiga-like toxin genes in Escherichia coli. In: Persing DH, Smith TF, Tenover FC, White TJ, editors. Diagnostic Molecular Microbiology Principles and Applications. Washington, DC, USA: American Society for Microbiology; 1993. pp. 271-276.
10. Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D betalactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45: 583-588.
11. Poirel L, Heritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22.
12. Poirel L, Marqué S, Hẻriter C, Segonds C, Chabanon G, Nordmann P. OXA-58, a novel class D (beta)-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 202-208.
13. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 2011; 70: 119-123.
14. Giordano A, Varesi P, Bertini A, Villa L, Dionisi AM, Venditti M, Carfagna P, Luzzi I, Mancini C, Carattoli A. Outbreak of Acinetobacter baumannii producing the carbapenemhydrolyzing oxacillinase OXA-58 in Rome, Italy. Microb Drug Resist 2007; 13: 37-43.
15. Gogou V, Pournaras S, Giannouli M, Voulgari E, Piperaki ET, Zarrilli R, Tsakris A. Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: a 10 year study in Greece (2000-09). J Antimicrob Chemother. 2011; 66: 2767- 2772.
16. Di Popolo A, Giannouli M, Triassi M, Brisse S, Zarrilli R. Molecular epidemiological investigation of multidrug-resistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme. Clin Microbiol Infect 2011; 17: 197-201.
17. Boo TW, Walsh F, Crowley B. First report of OXA-23 carbapenemase in clinical isolates of Acinetobacter species in the Irish Republic. J Antimicrob Chemother 2006; 58: 1101- 1102.
18. Brigante G, Migliavacca R, Bramati S, Motta E, Nucleo E, Migliorino G, Pagani L, Luzzaro F, Vigano FE. Emergence and spread of a multidrug-resistant Acinetobacter baumannii clone producing both the carbapenemase OXA-23 and the 16S rRNA methylase ArmA. J Med Microbiol 2012; 61: 653-661.
19. Bonnin RA, Poirel L, Licker M, Nordmann P. Genetic diversity of carbapenem-hydrolysing β-lactamases in Acinetobacter baumannii from Romanian hospitals. Clin Microbiol Infect 2011; 17: 1524-1528.
20. Liakopoulos A, Miriqoau V, Katsifas EA, Karaqouni AD, Daikos GL, Tzouvekelis LS, Petinaki E. Identification of OXA23-producing Acinetobacter baumannii in Greece (2000-09). Euro Surveill 2012; 17: 11.
21. Schleicher X, Higgins PG, Wisplinghoff H, Körber-Irrgang B, Kresken M, Seifert H. Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005-2009). Clin Microbiol Infect 2013; 19: 737-742.
22. Marqué S, Poirel L, Héritier C, Brisse S, Blasco MD, Filip R, Coman G, Naas T, Nordman P. Regional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA58 in Acinetobacter spp. in Europe. J Clin Microbiol 2005; 43: 4885-4888.
23. Coelho J, Woodford N, Afzal-Shah M, Livermore D. Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents. Antimicrob Agents Chemother 2006; 50: 756-758.
24. Poirel L, Nordmann P. Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-58 in Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 1442-1448.
25. Sohrabi N, Farajnia S, Akhi MT, Nahaei MR, Naghili B, Peymani A, Amiri Z, Rezaee MA, Saeedi N. Prevalence of OXA-type β-lactamases among Acinetobacter baumannii isolates from Northwest of Iran. Microb Drug Resist 2012; 18: 385-389.
26. Ergin A, Hasçelik G, Eser OK. Molecular characterization of oxacillinases and genotyping of invasive Acinetobacter baumannii isolates using repetitive extragenic palindromic sequence-based polymerase chain reaction in Ankara between 2004 and 2010. Scand J Infect Dis 2013; 45: 26-31.
27. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008; 8: 751-762.
28. Vila J, Pachon J. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother 2012; 13: 2319-2336.
29. Jones RN, Ferraro MJ, Reler LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007; 45: 227-230.
30. Thamlikitkul V, Tiengrim S, Tribuddharat C. Comment on: High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 60: 177-178.